Federal Register / Vol. 79, No. 223 / Wednesday, November 19, 2014 / Notices 68893 

4. US Application No. 12/177,012, 

filed July 21, 2008 and issued as US 

patent 8,216,788 on July 10, 2012 [HHS 

Ref. No E–109–2007/1–US–02]; 

5. US Application No. 13/489,321, 

filed June 5, 2012 [E–109–2007/1–US– 

04]; 

6. US Application No. 14/263,703, 

filed April 28, 2014 [E–109–2007/1–US– 

011] 

The patent rights in these inventions 

have been assigned to the United States 

of America. 

The prospective exclusive licensed 

territory may be worldwide and the 

field of use may be limited to in vitro 

diagnostics of prion-associated diseases 

requiring FDA premarket approval, or 

the equivalent thereof outside of the 

United States, and USDA licensed 

veterinary diagnostics, or the 

equivalents thereof outside of the 

United States. 

DATES: Only written comments and/or 

application for a license that are 

received by the NIH Office of 

Technology Transfer on or before 11:59 

p.m. Eastern Time on December 19, 

2014 will be considered. 

ADDRESSES: Requests for a copy of the 

patents and applications, inquiries, 

comments and other materials relating 

to the contemplated license should be 

directed to: Tedd Fenn, Senior 

Licensing and Patenting Manager, Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Email: fennea@

mail.nih.gov; Telephone: 424–297– 

0336; Facsimile: 301–402–0220. 

SUPPLEMENTARY INFORMATION: The 

invention relates to methods and 

compositions for the detection of 

infectious prions and diagnosis of prion 

related diseases. Currently, available 

tests for disease-causing prions are 

incapable of detecting low 

concentrations and must be confirmed 

post-mortem. This technology enables 

rapid and economical detection of sublethal concentrations of prions by using 

recombinant protein (rPrP-sen) as a 

marker. A seeded sample polymerizes 

rPrP-sen, which is detected as an 

amplified indicator of prions in the 

sample. This assay does not require 

multiple amplification cycles unless a 

higher degree of sensitivity is required. 

This technology potentially may be 

combined with additional priondetection technologies to further 

improve the sensitivity of the assay. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR Part 404. The 

prospective exclusive license may be 

granted unless within thirty (30) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR Part 404. 

Any additional applications for a 

license in the field of use, filed in 

response to this notice, will be treated 

as objections to the grant of the 

contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: November 10, 2014. 

Richard U. Rodriguez, 

Acting Director, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2014–27342 Filed 11–18–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel Targeting Latently Infected 

Cells Without Reactivation (RO1). 

Date: December 8–9, 2014. 

Time: December 8, 2014, 10:00 a.m. to 6:00 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Room 

4H100, MSC 9823, 5601 Fishers Lane, 

Bethesda, MD 20817 (Telephone Conference 

Call). 

Time: December 9, 2014, 10:00 a.m. to 6:00 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Room 

3F100, MSC 9823, 5601 Fishers Lane, 

Bethesda, MD 20817 (Telephone Conference 

Call). 

Contact Person: Robert C. Unfer, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, DEA/NIAID/NIH/DHHS, 5601 

Fishers Lane, Room 3F40B, MSC 9823, 

Rockville, Maryland 20892, 240–669–5035, 

unferrc@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: November 12, 2014. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–27340 Filed 11–18–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Heart, Lung, and Blood 

Advisory Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Advisory Council. 

Date: February 10, 2015. 

Open: 8:00 a.m. to 1:00 p.m. 

Agenda: To discuss program polices and 

issues, including the Asthma Guidelines 

Needs Assessment Report. This report can be 

found at http://www.nhlbi.nih.gov/health/

resources/lung/nhlbac-asthma-report.htm 

and comments may be submitted to Asthma_

Needs_Assessment_Comments@nhlbi.nih.gov 

by January 5, 2015. 

mstockstill on DSK4VPTVN1PROD with NOTICES